Tisotumab vedotin, 1418731-10-8, targets tissue factor (TF), a protein overexpressed in certain cancers. It combines a TF-specific monoclonal antibody (TF-011) with MMAE, a powerful microtubule disruptor. A covalent linker ensures precise delivery to cancer cells. This ADC exhibits both immunomodulatory and anti-tumor activities.
Key Features
- Targeted Therapy: Specifically binds to TF, directing MMAE to cancer cells.
- Mechanism of Action: Enters cancer cells after binding to TF and releases MMAE to disrupt microtubules, halting cell division and causing cancer cell death.
- Dual Action: Combines anti-tumor effects with immune system modulation.
Applications
- Cervical Cancer: Used in advanced or metastatic cases where TF is overexpressed.
- Solid Tumors: Investigated for other cancers with high TF expression, including ovarian and head and neck cancers.
Tisotumab vedotin offers a targeted approach to treating advanced cancers, providing both direct anti-tumor effects and potential immune system benefits.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.